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illtraviolet radiation has been found to alter the dis-
tribution and function of human lymphocytes. To deter-
mine whether photochemotherapy (PUV A) alters circu-
lating levels of T cell subset marker-bearing lympho-
cytes, cells from 9 patients with psoriasis undergoing 
PUV A therapy for several years (mean 4.6 ± 1.4 yr), 17 
patients with active untreated psoriasis, and 20 healthy 
volunteers were reacted with monoclonal antibodies to 
T cell surface markers, including OKT3 (all peripheral 
blood T cells), OKT4 (helper/inducer T cells), OKT6 
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'(common thymocytes), and ORT8 (suppressor/cytotoxic 
T cells), and analyzed by flow cytometry. There were no 
differences in the distribution of T cell subsets between 
healthy volunteers and patients with active psoriasis. In 
contrast, the percentages of lymphocytes reacting with 
OKT3 and OKT4 were lo~er (by 16% and 12% percent 
.respectively, p < 0.0025) in the PUV A-treated patients 
compared to healthy volunteers or patients with active 
psoriasis that had not received PUV A therapy. There 
was no difference in the percentage of OKTS and OKT6 
bearing cells. Squamous cell carcinoma of the skin sub-
sequently developed in 2 of 3 PUV A-treated patients 
with 'the lowest percentages of T4-bearing cells. These 
findings indicate that long-term PUV A therapy is asso-
ciated with a reduction in circulating helper/inqucer T 
cells. This reduction may have a . role in tile altered 
immune function reported in PUV A-treated patien~s. 
Ultraviolet radiation can alter the distribution and function 
of lymphocytes both in animal$' and humans [1-6]. Oral psora-
len and subsequent exposUl'e tb ul.traviolet-A radiation (PUYA) 
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constit u tes a n effective and widely used thera py for psorias is. 
Recen t studies suggest that PUV A t h erapy m ay affect the 
immune system [7- 10]. A single dose of PUVA tra ns iently 
d ecreased t h e number of circula ting T cells [11]. Transient 
impairm ent of t h e response of lymphocytes to the mitogen 
phytoh e m agglutinin (PHA) , occurred dur ing an initial course 
of t r eatm en t with PUV A [11]. A majority of pa tients undergo-
ing treatment with PUV A showed diminish ed responsiven ess 
to dinitrochlorobenzen e [12]. 
R ecently, monoclonal antibodies to subsets of human T cells 
h ave been d eveloped and ch aract erized [13]. In the prese nt 
study, these reagents a nd automat ed flow cytometry were u sed 
to d et ermine whether pr olonged therapy with PUV A alters the 
distribut ion of T cell subsets in peripheral blood. Both normal 
individuals and patients with psoriasis not undergoing PUV A 
therapy were studied as control popula tions . 
MATERIALS AND METHODS 
Nine PUV A-treated patients were examined. These patients had 
been treated for 4.6 ± 1.4 yr (mean ± 1 SD); each had received more 
than 200 individual phototherapy exposures with an average total 
exposure of 3766 ± 1317 joules/m2 of sur face area (mean ± SD) . At the 
time of examination, their disease was well controlled. Seventeen 
patients with active psoriasis involving at least 20% of total body surface 
area who had not received P UV A therapy (designated "untreated" 
patients) and 20 normal volunteers were studied as controls. Blood 
samples from PUV A-treated patients were obtained 4 to 7 days after 
the last treatment. Age, sex, race, duration of psoriasis, area of skin 
involvement, activity of current psoriatic disease, type of psoriasis, 
presence of arthrit is, intercurrent diseases, smoking history, prior med-
ication and prior exposure to phototherapy were surveyed among the 
untreated psoriasis group. In addition, in the PUV A-treated group, 
susceptibility to sunburn (skin type), duration of phototherapy, number 
of treatments, and total exposure dose of PUV A radiation were noted. 
The mean age of the PUVA-treated group was 49.2 ± 14 .1 yr. The ratio 
of male to female was 2:7. The mean ages of the untreated psoriatic 
patients and the normal volunteers were 29.2 ± 11.5 and 36.B ± 17.B yr., 
respectively. The ratio of males to females was 1:1 in both groups. 
Monoclonal antibodies to human T cell subsets were obta ined from 
Ortho P harmaceuticals (Raritan, N .J .). The specificity of these anti-
bodies has been previously described [13-17]' Our panel included 
antibodies to surface components of all mature peripheral blood T cells 
(OKT3), T helper/ inducer cells (OKT4), the majority of thymocytes 
(OKT6), and T suppressor/cytotoxic cells (OKTB). Controls included 
ascites fluid from mice bearing the P3X63AgU I myeloma cells. Fluo-
rescein-conjugated IgG fraction of goat antimouse IgG (heavy and light 
chains specific) antiserum was obtained from Cappel Laboratories 
(Cochranville, PA) . 
Lymphocytes were stained and analyzed as described previously 
[IB,19]. In brief, peripheral blood from each subject was obtained and 
anticoagulated wi th sodium citrate. The buffy coat was sepru'a ted and 
50 III of this cell suspension was dispensed into sample tubes, cells were 
incubated with individual monoclonal antibodies or mouse ascites fluid 
for 30 min at 4°C. The cells were suspended in a solution of 0.15 M 
NH,CI, 0.01 M KHC0 3 and 0.1 ruM EDTA to lyse the erythrocytes and 
were washed with phosphate-buffered (0.01 M, pH 7.4) saline (PBS). 
After centrifugation, the cells were incubated with diluted flu orescein-
conjugated goat antimouse IgG antibodies for 30 min at 4°C. After 
washing, the cells were suspended in PBS. In some experiments, stained 
cells were fixed in 1% paraformaldehyde for 5 min a t 4°C and stored at 
4°C fo r up to 24 hr before analysis. Fixation did not alter the percentage 
of stained cells (unpublished observations) [20]. 
Each sample was examined with a prototype Spectrum III au tomated 
flow cytometer (Ortho Diagnostic Systems, Westwood, MA) . By utiliz-
ing 90° angle and forward angle light scattering properties of the cells, 
it wa.s possible to identify and analyze lymphocytes as a population 
distinct from monocytes and granulocytes [18]. The threshold for 
posit ive fluorescence was selected so that less than 1% of cells incubated 
with control asc ites fluid were scored as positive. 
T he total number of lymphocytes was calculated from the total white 
blood cell count (determined by Coulter counter) and the percentage 
of lymphocytes se~n on a stained smear pf peripheral blood. 
Data are expressed as the mean value ± 1 SD. Data were compared 
among the 3 groups and a p -value of less than 0.05, as calculated by the 
Wilcoxon test, was regarded as significant. The Fisher exact method 
was used to examine the relationship of age to levels of OKT4 reactive 
cells in the group of normal volunteers. 
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RESULTS 
Lymphocyt es b earing T cell subset markers were iden t ified 
with monoclonal antibodies to the T 3, T4, T6 a nd T8 markers 
(Ta ble and Figure). The mean percentage of lymphocytes r e-
active with the OKT3 reagent was lower in p a tients treated 
with PUVA tha n in untreated patients (p < 0.005) or h ealthy 
TA B L E Distribution of T cell subset m arJ,er -bearing lymphocytes in 
patients with psoriasis and controls 
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Distribution of individual values of percentages of T cell subsets in 
patients with psoriasis, patients with psoriasis treated with long- term 
PUV A therapy and healthy controls. 
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controls (p < 0.0025). The mean percentage of lymphocytes 
reactive with OKT 4 reagent was also lower in PUV A- treated 
patients compared to untreated patients or normal controls 
(both p < 0.0025). T here was no significan t diffe rence among 
th e 3 groups in the percentage of lymphocytes reactive with 
OKT 6 or OKT 8 reagents (p > 0.05). T he total lym phocyte 
coun t for t he P UV A- treated patients was 2057 ± 284 per mm'] 
and for the untreated patients, 1891 ± 291; t his difference was 
not significant. 
There was no systematic diffe rence in T cell subset distribu-
tion between untreated patients with active psoriasis and 
healthy volun teers ( p > .05). None of t he clinical factors 
reviewed could be discerned to correlate with T cell subset 
fTact ions in unt reated psoriasis patients. 
Older normals had a somewhat higher percentage of OKT4 
reactive cells. Four of 5 of t he healthy controls a bove age 45, 
bu t only 2 of 15 below age 45, had a percentage of T4-bearing 
lymphocytes greater t han 40% (p < 0.05). There was no rela-
t ionship between the sex of t he normal vo lunteers and the 
percentage of T cell subset marker -bearing lymphocytes. 
The relationship between the percentage of lymphocytes 
bearing various subset ma rkers and clinical features of t he 
PUV A-treated patients were examined. Two of three PUV A-
treated patients with less than 30% T4-bearing cells developed 
squamous cell ca rcinoma of the skin wi thin the two month 
fo llowing the T cell studies. One of these patients developed a 
single neoplasm and the other patient developed 9 tumors. T he 
latter patient had a reduction in total lymphocytes to 688/ mm'l 
and a ma rked decrease in percen tage of T3 (13.5%) and T8 
(12.8%) bearing cells. The PU VA-treated patients were signifi-
can tly older than the un treated patients ( p < 0.005), there was 
no significant difference in age of the untreated patients com-
pared to normal controls (p > 0.05). T here was no correlation 
between any other clinical feature ofthe PUV A-treated patients 
and the levels of the various subsets. Of par ticul ar note, no 
correlation could be discerned between the total dose or fre-
quency of irrad iation and individual levels of T4-bearing cells. 
DISCUSSION 
Monoclonal antibodies to surface markers ofT cell subsets 
were utilized to study peripheral blood lymphocytes fTom pa-
t ients on long- term PUV A therapy, psoriatic patients not re-
ceiving P UVA therapy and normal volun teers. T he results of 
this study indicate that chronic PUV A therapy of psoriatic 
patients is associated with a reduced fraction of circula ting '1' 
cells; this reduction was not seen in t he un t reated patien ts with 
psoriasis. T he reduction in percentage of T cells involved t he 
subset associated with helper/ inducer function. One patient, 
who had the lowest percentage of T cells, also showed a reduc-
tion of the suppressor/cytotoxic cell population. Although the 
PU V A-t reated patients were significantly older than either the 
untreated patients or healthy controls, the '1' cell subset alter -
ations observed could not be attribu ted to age, because older 
normals showed a s light increase in t he percentage of '1'4-
bea ring cells. While a greater propo rtion of the PUV A-treated 
group was female when compar ed to either control group, it is 
doubtfu l t hat th e T cell alterations could be due to the sex of 
the subjects because there was no correlation between sex and 
the levels of various '1' cell subsets in any of the 3 groups. No 
significant correlation was appar ent in the treated and un -
treated groups when age and sex were considered together. 
T he total number of lymphocytes in most PUV A-treated 
patients was not reduced; t herefore, the decrease in T3-bearing 
cells was proba bly accompanied by an expansion in either t he 
B cell or null cell compar tment. 
The normal distribu tion ofT cell subsets fo und in untreated 
psoriasis patients is consistent wi th data recently presented 
[20]. H owever , Sauder, Bailin, Sundeen, and Krakauer, using a 
functional assay, have repor ted diminished suppressor cell ac-
tivity in psoriatic patients [22]. S ince the percen tage and, 
presuma bly, the a bsolu te number of T8- bea ring cells is normal 
in untreated psoriatic patients, t he diminished function ob-
served does not appear to be related to a reduction in the 
num ber of suppressor/ cytotoxic T cells. Functional abnormal-
it ies in a '1' cell subset present in normal numbers has recently 
been repor ted [23]. . 
T he functions of T4-bearing cells have been defined by 
Reinherz, Schlossman and their associates [24]. T hese cells 
undergo proliferation in response to stim ulation with soluble or 
cell surface an tigens as well as the mitogens concanavalin A 
(Con A) and phytohemagglutinin (PHA). In contrast, T8-bear-
ing cells failed to respond to soluble antigens and showed a 
diminished response to optimal doses of PHA and were unre-
sponsive at suboptimal doses. Although T4-bearing cells were 
capable of proliferating in response to alloan tigens, they did not 
become cytotoxic; T8-bearing cells contained a cytotoxic effec-
tor population. However, T4-bearing inducer/ helper lympho-
cytes were required for optimal generation ofT cell cytotoxicity 
[25]. 
In parallel studies [26] we fo und that the response to mitogens 
was reduced in blood lymphocytes from 10 patients on long-
term PUV A treatments for psoriasis, some of these patients 
were included in the present study. Reduced responsiveness of 
lymphocytes to P H A was fo und in 5 patients. T hese 5 patients 
had the greatest reduction in t he percentage of T4-bearing cells 
(to levels that were 2 standard deviations lower than the normal 
mean). T he posit ive correlation between a reduction in t he 
percentage of T4-bearing cells and reduced responsiveness to 
P H A, lends functional significance to th e observations reported 
herein. 
Patien ts receiving long-term PUV A therapy have an in-
creased incidence of cutaneous squamous cell carcinoma [27]. 
Squamous cell carcinoma developed in 2 of 3 patients with the 
lowest fractions of T 4-bearing cells; whether t hese two ph enom-
ena a re related is not proved. Our series is too small to reach 
statistical significance. It must be pointed out that the incidence 
of squamous cell carcinoma in patien ts receiving long-term 
PUV A therapy is closely linked to prior r isk on th e basi of 
exposure to other carcinogenic agents, i. e., a history of x-irra-
diation or arsenic treatment. Neither of the 2 patients who 
developed tumors in t his study had received such therapy nor 
had t hey had prior tumors. A relative deficiency of T4-bearing 
cells might impair t he induction of the cytotoxic responses to 
tumors. 
Our data do not provide an explanation for the decrease in 
T4- bearing cells associated with PUV A therapy, but th ey do 
correlate with cer tain functional data. It is apparent that suffi-
cient UV A ligh t penetrates the epidermis to affect peripheral 
blood lymphocyte populations [10,28]. T he selective decrease 
in T4-bearing cells in PUV A-treated patients suggests that 
these helper T cells are more susceptible to PUV A treatment 
th an T8-bearing cells. Possibly the circulation of T4-bearing 
cell d iffe rs from that of T8- bearing cells, T4-bearing cells may 
localize in the epidermis where greater exposure to UVA can 
occur. P rospective studies ar e required to determine whether a 
decrease in percentage of T4-bearing lymphocytes identifies 
those patients who will achieve a remis ion of PUV A therapy 
and whether a marked decrease forecasts the development of 
skin tumors in t reated patients. 
We a.re indebted to G. Goldstein and P . Kung (Ortho P harmaceuti-
cals, Rari tan, N.J.) for providing the monoclonal antibodies, to Dr. 
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The regulatory mechanisms for collagenase synthesis 
in recessive dystrophic epidermolysis bullosa (RDEB) 
have been studied using messenger RNA (mRNA) har-
vested from normal and RDEB skin fibroblasts to direct 
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Abbreviations: 
EDT A: ethylenediaminetetracetic acid 
Hepes: hyclroxyethylpiperazine-N' -2-ethanesulfonic acid 
mRNA: messenger RNA 
RDEB: recessive dystrophic epidermolysis bu llosa 
SDS: sodium dodecyl sulfate 
protein synthesis in a rabbit reticulocyte lysate transla-
tion system. Fibroblast mRNA encoded the synthesis of 
- 60,000 and -55,000 dalton forms of procollagenase in 
cell-free translation_ In contrast to biosynthesis by intact 
cells, there was preferential translation of the -60,000 
dalton specie. For quantitative comparisons with mRNA 
from normal cells, mRNA was harvested from fibroblasts 
of 2 RDEB patients whose intact cells have been docu-
mented to have increased synthesis of collagenase_ Al-
though total translational activity was equal in normal 
and RDEB mRNA preparations, translatable collagenase 
mRNA was increased 3.5- to 10-fold, suggesting that the 
enhanced collagenase synthe:;is characteristic of RDEB 
is due to increased concentrations or preferential trans-
lation of collagenase mRNA. 
Because of its unique ability to initiate collagen degradation, 
human skin fibroblas t collagenase plays a key role in both 
normal and pathologic connective tissue m e tabolism [2). In 
